These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 25041859)

  • 1. Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitis.
    Wolf D; D'Haens G; Sandborn WJ; Colombel JF; Van Assche G; Robinson AM; Lazar A; Zhou Q; Petersson J; Thakkar RB
    Aliment Pharmacol Ther; 2014 Sep; 40(5):486-97. PubMed ID: 25041859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2.
    Sandborn WJ; Colombel JF; D'Haens G; Van Assche G; Wolf D; Kron M; Lazar A; Robinson AM; Yang M; Chao JD; Thakkar R
    Aliment Pharmacol Ther; 2013 Jan; 37(2):204-13. PubMed ID: 23173821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn's disease.
    Sandborn WJ; Colombel JF; D'Haens G; Plevy SE; Panés J; Robinson AM; Pollack PF; Zhou Q; Castillo M; Thakkar RB
    Curr Med Res Opin; 2013 May; 29(5):483-93. PubMed ID: 23438483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study.
    Leonardi C; Sobell JM; Crowley JJ; Mrowietz U; Bao Y; Mulani PM; Gu Y; Okun MM
    Br J Dermatol; 2012 Sep; 167(3):658-67. PubMed ID: 22564148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 52-week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants.
    Reinisch W; Sandborn WJ; Panaccione R; Huang B; Pollack PF; Lazar A; Thakkar RB
    Inflamm Bowel Dis; 2013 Jul; 19(8):1700-9. PubMed ID: 23665965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ; van Assche G; Reinisch W; Colombel JF; D'Haens G; Wolf DC; Kron M; Tighe MB; Lazar A; Thakkar RB
    Gastroenterology; 2012 Feb; 142(2):257-65.e1-3. PubMed ID: 22062358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3.
    Colombel JF; Sandborn WJ; Ghosh S; Wolf DC; Panaccione R; Feagan B; Reinisch W; Robinson AM; Lazar A; Kron M; Huang B; Skup M; Thakkar RB
    Am J Gastroenterol; 2014 Nov; 109(11):1771-80. PubMed ID: 25155227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial.
    Kimball AB; Kerdel F; Adams D; Mrowietz U; Gelfand JM; Gniadecki R; Prens EP; Schlessinger J; Zouboulis CC; van der Zee HH; Rosenfeld M; Mulani P; Gu Y; Paulson S; Okun M; Jemec GB
    Ann Intern Med; 2012 Dec; 157(12):846-55. PubMed ID: 23247938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Escalation of Adalimumab Therapy to Weekly Dosing in Pediatric Patients with Crohn's Disease.
    Dubinsky MC; Rosh J; Faubion WA; Kierkus J; Ruemmele F; Hyams JS; Eichner S; Li Y; Huang B; Mostafa NM; Lazar A; Thakkar RB
    Inflamm Bowel Dis; 2016 Apr; 22(4):886-93. PubMed ID: 26950307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial.
    Reinisch W; Sandborn WJ; Hommes DW; D'Haens G; Hanauer S; Schreiber S; Panaccione R; Fedorak RN; Tighe MB; Huang B; Kampman W; Lazar A; Thakkar R
    Gut; 2011 Jun; 60(6):780-7. PubMed ID: 21209123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
    Colombel JF; Sandborn WJ; Rutgeerts P; Kamm MA; Yu AP; Wu EQ; Pollack PF; Lomax KG; Chao J; Mulani PM
    Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis.
    Feagan BG; Sandborn WJ; Lazar A; Thakkar RB; Huang B; Reilly N; Chen N; Yang M; Skup M; Mulani P; Chao J
    Gastroenterology; 2014 Jan; 146(1):110-118.e3. PubMed ID: 24067881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study.
    Croft NM; Faubion WA; Kugathasan S; Kierkus J; Ruemmele FM; Shimizu T; Mostafa NM; Venetucci M; Finney-Hayward T; Sanchez Gonzalez Y; Bereswill M; Lazar A; Turner D
    Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):616-627. PubMed ID: 34153231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.
    Sandborn WJ; Hanauer SB; Rutgeerts P; Fedorak RN; Lukas M; MacIntosh DG; Panaccione R; Wolf D; Kent JD; Bittle B; Li J; Pollack PF
    Gut; 2007 Sep; 56(9):1232-9. PubMed ID: 17299059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term assessment of clinical response to adalimumab therapy in refractory ulcerative colitis.
    Hussey M; Mc Garrigle R; Kennedy U; Holleran G; Kevans D; Ryan B; Breslin N; Mahmud N; McNamara D
    Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):217-21. PubMed ID: 26587866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab.
    Afif W; Leighton JA; Hanauer SB; Loftus EV; Faubion WA; Pardi DS; Tremaine WJ; Kane SV; Bruining DH; Cohen RD; Rubin DT; Hanson KA; Sandborn WJ
    Inflamm Bowel Dis; 2009 Sep; 15(9):1302-7. PubMed ID: 19408340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
    Trinder MW; Lawrance IC
    J Gastroenterol Hepatol; 2009 Jul; 24(7):1252-7. PubMed ID: 19220669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.
    Colombel JF; Sandborn WJ; Rutgeerts P; Enns R; Hanauer SB; Panaccione R; Schreiber S; Byczkowski D; Li J; Kent JD; Pollack PF
    Gastroenterology; 2007 Jan; 132(1):52-65. PubMed ID: 17241859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease.
    Kiss LS; Szamosi T; Molnar T; Miheller P; Lakatos L; Vincze A; Palatka K; Barta Z; Gasztonyi B; Salamon A; Horvath G; Tóth GT; Farkas K; Banai J; Tulassay Z; Nagy F; Szenes M; Veres G; Lovasz BD; Vegh Z; Golovics PA; Szathmari M; Papp M; Lakatos PL;
    Aliment Pharmacol Ther; 2011 Oct; 34(8):911-22. PubMed ID: 21883326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis.
    Suzuki Y; Motoya S; Hanai H; Hibi T; Nakamura S; Lazar A; Robinson AM; Skup M; Mostafa NM; Huang B; Thakkar R; Watanabe M
    J Gastroenterol; 2017 Sep; 52(9):1031-1040. PubMed ID: 28321512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.